Form 4: Regeneron Director Sells Stock Under 10b5-1 Plan

Regeneron Pharmaceuticals Director Arthur F. Ryan reported the sale of common stock under a pre-arranged trading plan.

Summary

• Director Arthur F. Ryan of Regeneron Pharmaceuticals, Inc. (REGN) has reported transactions involving the sale of common stock.
• These sales were executed under a Rule 10b5-1(c) trading plan adopted on October 31, 2025.
• The transactions occurred on April 1, 2026, with sales reported at various volume-weighted average prices.
• Following these transactions, Mr. Ryan beneficially owns 17,603 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider stock sales under a pre-established plan, which is a common and expected corporate action.

Negatives

• Director Arthur F. Ryan sold a total of 150 shares of Regeneron Pharmaceuticals common stock on April 1, 2026.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider stock transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-planned strategy for stock sales, often used by executives and directors to diversify holdings or manage personal finances without the appearance of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the sale of shares by a director, which could be interpreted in various ways, though the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, SEC Filing